The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Targeting Polo-like Kinase in Cancer Therapy
Abstract
Polo-like kinases (Plk) function in mitosis and maintaining DNA integrity. There are four family members, of which Plk1 represents a target for anticancer therapy. Plk1 is only expressed in dividing cells with peak expression during G2/M. Plk1 functions in multiple steps of mitosis, and is overexpressed in many tumor types. Mitotic arrest and inhibition of proliferation, apoptosis, and tumor growth inhibition have been observed in preclinical studies using small interfering RNAs (siRNA) or small molecules that inhibit Plk1. Preclinical studies also show that Plk1 inhibitors may be active against tumors with RAS mutations and that tumor cells with mutations in TP53 are more sensitive to inhibition of Plk1. Several Plk inhibitors are in phase I or II clinical studies. As expected, hematologic toxicity is the primary dose-limiting toxicity. Some patients have achieved clinical response, although in some studies only at doses above the maximum tolerated dose defined in the study. Further evaluation is necessary to discern the clinical utility of Plk1 inhibitors. Clin Cancer Res; 16(2); 384–9
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The spindle-assembly checkpoint in space and time
Musacchio, A., & Salmon, E. D. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2163 · Cited by 2,227
On the road to cancer: aneuploidy and the mitotic checkpoint
Kops, G. J. P. L., Weaver, B. A. A., & Cleveland, D. W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1714 · Cited by 1,185
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017
BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo
Steegmaier, M., Hoffmann, M., Baum, A., Lénárt, P., Petronczki, M., Krššák, M., Gürtler, U., Garin-Chesa, P., Lieb, S., Quant, J., et al. (2007) · Current Biology · doi:10.1016/j.cub.2006.12.037 · Cited by 834
Lane, H. A., & Nigg, E. A. (1996) · The Journal of cell biology · doi:10.1083/jcb.135.6.1701 · Cited by 690
Golsteyn, R. M., Mundt, K. E., Fry, A. M., & Nigg, E. A. (1995) · The Journal of cell biology · doi:10.1083/jcb.129.6.1617 · Cited by 473
polo encodes a protein kinase homolog required for mitosis in Drosophila.
Llamazares, S., Moreira, A., Tavares, A., Girdham, C., Spruce, B. A., Gonzalez, C., Karess, R. E., Glover, D. M., & Sunkel, C. E. (1991) · Genes & Development · doi:10.1101/gad.5.12a.2153 · Cited by 404
Polo-like Kinase-1 Controls Recovery from a G2 DNA Damage-Induced Arrest in Mammalian Cells
van Vugt, M. A. T. M., Brás, A., & Medema, R. H. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.07.015 · Cited by 385
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent
Gumireddy, K., Reddy, M. V. R., Cosenza, S. C., Nathan, R. B., Baker, S. J., Papathi, N., Jiang, J., Holland, J., & Reddy, E. P. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.009 · Cited by 367
Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase
Toyoshima-Morimoto, F., Taniguchi, E., Shinya, N., Iwamatsu, A., & Nishida, E. (2001) · Nature · doi:10.1038/35065617 · Cited by 364
Cited by
Knocking down disease: a progress report on siRNA therapeutics
Wittrup, A., & Lieberman, J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3978 · Cited by 804
Shared and separate functions of polo-like kinases and aurora kinases in cancer
Lens, S. M. A., Voest, E. E., & Medema, R. H. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2964 · Cited by 597
PLK1, A Potential Target for Cancer Therapy
Liu, Z., Sun, Q., & Wang, X. (2017) · Translational Oncology · doi:10.1016/j.tranon.2016.10.003 · Cited by 454
Kietzmann, T., Mennerich, D., & Dimova, E. Y. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00011 · Cited by 176
Clinical significance of Polycomb gene expression in brain tumors
Crea, F., Hurt, E. M., & Farrar, W. L. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-265 · Cited by 70
Metadata
- Authors
- Degenhardt, Y., & Lampkin, T.
- Venue
- Clinical Cancer Research
- Published
- 2010-01-14
- Volume
- 16
- Issue
- 2
- Pages
- 384-389
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2110864471
- Cited by
- 262
- References
- 62
- FWCI
- 9.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Polo-like Kinase in Cancer Therapy. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-09-1380
- The paper
- Degenhardt, Y., & Lampkin, T. (2010). Targeting Polo-like Kinase in Cancer Therapy. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-09-1380
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.